Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

Prior treatment with an ATM inhibitor

Past medical history of an inflammatory type(interstitial) lung disease or current inflammatory lung disease

Radiotherapy within the last 4 weeks, except palliative radiotherapy for bone pain relief

Prior treatment with drugs that may cause lung damage

Poor of lung function

History/presence of muscle weakness or abnormal blood tests relating to muscle function

Cancer affecting the spinal cord and/or brain unless asymptomatic and stable

Any evidence of severe or uncontrolled diseases, active bleeding,kidney transplant, or active infection including liver infections (hepatitis B, hepatitis C) and human immunodeficiency virus (HIV).

Evidence of severe lung infections

Receiving, or having received during the four weeks prior to starting study treatment other chemotherapy treatment for your cancer

Treatment with certain doses of steroids during the two weeks prior to starting study treatment

A known sensitivity to AZD0156 or any of its components

Treatment with any unapproved medicine within 28 days prior to starting study treatment

Receiving, or having received medications, herbal supplements and/or foods that significantly affect how your liver works

Low numbers of certain blood cells

If your liver and kidney aren't working normally

If your heart isn't working normally or you have a strong family history of certain heart diseases

Other cancers within the past 3 years, except for certain types of cervical and skin cancers

Sickness and vomiting, digestive diseases or previous significant bowel removal

Patients with uncontrolled fitting

Infections requiring treatment

Other severe and/or uncontrolled medical conditions in addition to your cancer

A blockage in your digestive system or severe bleeding from the stomach within 4 weeks before your take medication on the stuy

Patients with acute leukaemia or certain bone marrow diseases

Patients with a known sensitivity to olaparib or its components (Module 1), or components of FOLFIRI (Module 2)

Any previous treatment with drugs that work like olaparib. (Module 1 Only)

What this study is about